NClip

Psychopharmacology

8 min na pagbabasa

Psychopharmacology

Mahahalagang Punto

  • Pinagsasama ng psychopharmacology ang pharmacokinetics at pharmacodynamics upang i-optimize ang psychiatric outcomes.
  • Kabilang sa major drug classes ang antipsychotics, antidepressants, mood stabilizers, anxiolytics, hypnotics, at stimulants.
  • Kabilang sa nursing priorities ang adherence support, side-effect detection, safety monitoring, at client-centered education.
  • Mahalaga sa safe practice ang special-population dosing at interaction risk management.

Patopisyolohiya

Tinatarget ng mga psychotropic medication ang receptor at transporter pathways upang baguhin ang neurotransmission sa circuits na namamahala sa mood, thought, behavior, arousal, at cognition. Nakadepende ang drug response sa biologic target engagement at host factors, kabilang ang edad, organ function, genetics, comorbidity, at concurrent medications.

Lumalabas ang clinical effects at adverse effects mula sa receptor-level actions sa CNS at peripheral systems. Kaya dapat sabay na bigyang-kahulugan ang symptom improvement at safety monitoring, hindi bilang magkahiwalay na proseso.

Klasipikasyon

  • Pharmacokinetics: Ano ang ginagawa ng katawan sa gamot (absorption, distribution, metabolism, elimination).
  • Pharmacodynamics: Ano ang ginagawa ng gamot sa katawan (receptor interaction at physiologic response).
  • Biotransformation domain: Maaaring makabuluhang baguhin ng Phase I/II metabolism, lalo na ang CYP450 substrate-induction-inhibition patterns, ang serum exposure at adverse-effect risk.
  • Major psychotropic classes: Antipsychotics, antidepressants, mood stabilizers, anxiolytics, hypnotics, stimulants/non-stimulants.

Nursing Assessment

Pokus sa NCLEX

Unahin ang maagang pagtukoy sa severe adverse reactions at class-specific contraindication patterns.

  • Suriin ang baseline symptoms, kasalukuyang medications, at interaction risk bago ang initiation o dose changes.
  • Suriin ang class-specific adverse-effect patterns (halimbawa EPS, serotonin toxicity, lithium toxicity, sedation/fall risk).
  • Suriin ang adherence barriers kabilang ang stigma, cost, dosing burden, at side-effect distress.
  • Suriin ang special-population factors (pediatric, older adult, pregnancy/lactation, renal/hepatic function).
  • Suriin ang older-adult polypharmacy gamit ang formal medication reconciliation (prescribed, OTC, supplements) at Beers-criteria risk review.
  • Suriin ang pag-unawa ng client sa expected onset, warning signs, at emergency escalation points.
  • Suriin ang age-linked safety signals, kabilang ang suicidality surveillance para sa clients na mas bata sa 25 na nagsisimula o nagbabago ng antidepressants.
  • Suriin para sa behavioral activation o mixed/manic shifts pagkatapos ng antidepressant initiation o dose adjustment.
  • Suriin ang dietary at over-the-counter interaction risks para sa MAOI therapy (halimbawa tyramine-rich foods o pseudoephedrine use).
  • Suriin ang stimulant misuse/diversion risk at baseline cardiovascular status (blood pressure, pulse, chest pain/syncope history).

Nursing Interventions

  • Magbigay ng structured medication education gamit ang teach-back at plain language.
  • I-monitor ang objective at subjective response trends pagkatapos ng starts, stops, at titrations.
  • Agad na mag-escalate ng urgent adverse events at ipatupad ang safety precautions ayon sa protocol.
  • I-coordinate ang lab at program-based monitoring kung indicated (halimbawa lithium levels, clozapine ANC/REMS).
  • Makipagtulungan sa prescribers upang pasimplehin ang regimens at mapabuti ang long-term adherence.
  • Isama ang Beers-informed fall-prevention education at return-demonstration/teach-back para sa high-risk older-adult regimens.
  • Palakasin ang slow tapering plans para sa antidepressants at benzodiazepines upang mabawasan ang withdrawal risk at rebound symptoms.
  • Gumamit ng syndrome-focused triage kapag pinaghihinalaan ang severe reactions (halimbawa SHIVERS pattern para sa serotonin toxicity, rigidity/lagnat para sa posibleng NMS).

Side-Effect Normalization

Ang pagbalewala sa distressing side effects ay maaaring magtulak ng abrupt discontinuation at relapse risk.

Pharmacology

Kabilang sa mga pangunahing class highlights ang EPS at metabolic effects sa antipsychotics, serotonergic toxicity at discontinuation syndromes sa antidepressants, narrow therapeutic monitoring sa lithium, dependence at withdrawal risk sa benzodiazepines, complex sedation/fall profiles sa hypnotics, at cardiovascular/activation risks sa stimulant therapies. Klinikal ding mahalaga sa psychiatric settings ang adrenergic at cholinergic receptor effects; maaaring gamitin ang selected agents (halimbawa propranolol) upang bawasan ang severe anxiety-related autonomic symptoms, habang maaaring magpalala ng cognition at safety sa older adults ang anticholinergic burden.

Antidepressants

  • Ang SSRIs, SNRIs, NDRIs, trazodone, TCAs, at MAOIs ay may variable onset; kadalasang nangangailangan ng ilang linggo bago ang makabuluhang mood response.
  • Maaaring magdulot ng withdrawal syndromes ang abrupt discontinuation (flu-like symptoms, sleep disturbance, dizziness, mood instability, shock-like sensations); standard ang tapering.
  • Tumataas ang serotonin syndrome risk sa serotonergic combinations; sinusuportahan ng SHIVERS ang mabilis na bedside recognition (Shivering, Hyperreflexia, Increased temperature, Vital-sign instability, Encephalopathy, Restlessness, Sweating).
  • May hypertensive-crisis risk ang MAOIs kapag may tyramine-containing foods at sympathomimetics; nangangailangan ng emergency escalation ang severe headache, vision change, chest pain, at neurologic symptoms.

Mood Stabilizer: Lithium

  • Nananatiling core antimanic agent ang lithium na may narrow therapeutic range at kinakailangang serum monitoring (karaniwang 0.6-1.2 mEq/L).
  • May antisuicidal benefit ang lithium sa bipolar-spectrum illness at madalas nagsisimulang magpababa ng manic symptoms sa loob ng 1-3 weeks.
  • Maaaring lumitaw ang toxicity malapit sa therapeutic dosing; nangangailangan ng prompt level checks, dose hold, at supportive treatment ang early gastrointestinal at neurologic symptoms.
  • Kunin ang lithium levels 10-12 hours pagkatapos ng huling dose at palakasin ang hydration targets (about 1.5-3 L/day maliban kung may kontraindikasyon).
  • Maaaring pababain ng lithium ang renal concentrating ability at mag-precipitate ng nephrogenic diabetes insipidus; i-monitor ang polyuria/polydipsia at renal trends.
  • Sa anticonvulsant mood-stabilizer pathways, high-yield ang valproic-acid monitoring (typical therapeutic range 50-125 mcg/mL; tumataas ang toxicity risk above about 150 mcg/mL).
  • Maaaring pataasin ng interactions (halimbawa NSAIDs, dehydration, sodium/fluid shifts) ang lithium levels at toxicity risk.
  • Kabilang sa early lithium-toxicity cues ang gastrointestinal upset, drowsiness, muscle weakness, ataxia, tinnitus, at tumataas na dilute urine output.
  • Kabilang sa toxicity escalation ang provider notification, dose hold, hydration support, at dialysis consideration sa severe cases.

Anxiolytics and Sedative Agents

  • Binabawasan ng benzodiazepines ang acute anxiety at agitation ngunit may kasamang misuse, dependence, respiratory depression, at fall risk.
  • Maaaring magdulot ng profound sedation, coma, at kamatayan ang combined benzodiazepine-opioid exposure; iwasan ang co-prescribing kung maaari at mahigpit na mag-monitor kung hindi maiiwasan.
  • Hindi dapat ihinto nang biglaan ang long-term benzodiazepine use; kailangan ang structured tapering upang maiwasan ang severe withdrawal.
  • Ang buspirone ay non-benzodiazepine at nonaddictive ngunit hindi PRN-effective; kailangan nito ng scheduled daily dosing at delayed onset.
  • Iwasan ang pagsasama ng buspirone at MAOIs; maaaring pataasin ng serotonergic combinations (halimbawa kasama ng SSRIs/SNRIs) ang serotonin-toxicity risk.

Antipsychotics

  • Mas mataas ang risk ng EPS at tardive dyskinesia sa first-generation agents; maaaring maging airway emergency ang acute dystonia.
  • Binabawasan ng second-generation agents ang EPS risk ngunit pinapataas ang metabolic burden (weight, glucose, lipids); kailangan ang baseline at periodic metabolic monitoring.
  • Nangangailangan ang clozapine ng REMS participation na may ANC monitoring dahil sa agranulocytosis risk; dapat ituring na urgent cues ang fever/sore throat.
  • Maaaring baguhin ng tobacco-smoking status ang exposure sa selected antipsychotic pathways sa pamamagitan ng CYP induction, kaya maaaring kailanganing muling suriin ang dose plans kapag nagsimula o huminto ang paninigarilyo.
  • Ang neuroleptic malignant syndrome ay bihirang emergency na may hyperthermia at rigidity na umuunlad sa loob ng araw hanggang linggo; kailangan ang agarang discontinuation at supportive management. Maaaring kabilang sa associated lab cues ang elevated CPK/WBC/liver enzymes at myoglobinuria.
  • Maaaring isama sa severe NMS management ang dantrolene o bromocriptine bukod sa cooling/hydration at close electrolyte-vital monitoring.
  • Maaaring mangailangan ang persistent tardive dyskinesia ng VMAT2-pathway treatment strategies (halimbawa deutetrabenazine o valbenazine) pagkatapos ng antipsychotic reassessment.

Stimulants and SUD Pharmacotherapy

  • Ang ADHD stimulants ay Schedule II drugs na may abuse/diversion potential; mahalaga ang secure storage at misuse screening.
  • Maaaring magpataas ng blood pressure at heart rate ang stimulants at kaugnay ito ng bihira ngunit seryosong cardiovascular events; nangangailangan ng urgent evaluation ang chest pain, syncope, at exertional symptoms.
  • Kabilang sa common stimulant adverse effects ang insomnia, appetite suppression/weight loss, abdominal pain, at headache.
  • Kabilang sa less common effects ang motor/vocal tics at personality blunting; nangangailangan ng prompt prescriber reassessment ang paradoxical worsening.
  • Sa pediatric clients, i-monitor ang appetite, weight, at linear growth sa panahon ng stimulant titration.
  • Contraindicated ang stimulants sa panahon ng MAOI use at sa loob ng 14 araw pagkatapos ng MAOI discontinuation.
  • Mag-escalate nang urgent para sa stimulant-related mania, psychosis, peripheral vascular symptoms, o priapism; payuhan ang pag-iwas sa alcohol kasama ng extended-release stimulant formulations.
  • Madalas nangangailangan ng weekly symptom at adverse-effect checks sa loob ng about 1-3 months ang early dose optimization.
  • Kabilang sa medication-assisted treatment para sa opioid at alcohol use disorders ang buprenorphine-naloxone, methadone, naltrexone, acamprosate, at disulfiram; maaaring isama sa withdrawal protocols ang benzodiazepines para sa alcohol withdrawal at alpha-2 agonists para sa autonomic symptoms.

Aplikasyon ng Clinical Judgment

Klinikal na Sitwasyon

Isang client na kamakailang pinalitan ang antipsychotic formulation ay may jaw stiffness, neck spasms, restlessness, at hirap magsalita.

  • Recognize Cues: Acute extrapyramidal pattern pagkatapos ng medication transition.
  • Analyze Cues: Mataas ang posibilidad ng medication-induced adverse effect na nangangailangan ng urgent intervention.
  • Prioritize Hypotheses: Prayoridad ang immediate safety at reversal/mitigation ng adverse reaction.
  • Generate Solutions: I-activate ang EPS assessment protocol, i-notify ang provider, at ihanda ang indicated treatment.
  • Take Action: Ipatupad ang urgent management, i-monitor ang response, at muling suriin ang risk pagkatapos ng intervention.
  • Evaluate Outcomes: Kumpirmahin ang symptom reduction at rebisahin ang ongoing medication plan at education.

Mga Kaugnay na Konsepto

Graph View

Mga Backlink